JETD vs LABD

Key Takeaways

• JETD and LABD are both daily -3x inverse leveraged products but target entirely different sectors: airlines for JETD and biotechnology for LABD.
• JETD is structured as an exchange-traded note (ETN) issued by Bank of Montreal, while LABD is an open-ended exchange-traded fund (ETF) from Direxion.
• Expense ratios stand at 0.95% for JETD and 1.07% for LABD, reflecting the higher costs typical of leveraged inverse strategies.
• Both products provide synthetic exposure through derivatives and are designed for short-term tactical use rather than long-term holding due to compounding effects.
• Sector exposure differs sharply: JETD focuses on U.S. airlines, aircraft manufacturers, airfreight, and airport operators; LABD tracks an equal-weighted index of U.S. biotechnology companies.
• Structural distinctions include JETD’s note format with counterparty risk versus LABD’s fund structure with explicit swap and futures holdings.

Introduction

Investors seeking short-term inverse exposure to cyclical or growth-sensitive sectors often turn to leveraged products like JETD and LABD. These two exchange-traded vehicles do not compete directly; instead, they offer alternative bearish strategies within distinct industries—air transportation and biotechnology. The comparison highlights how structural features, underlying indexes, and thematic drivers shape their risk and positioning profiles in the current market environment.

MAX Airlines -3X Inverse Leveraged ETNs (JETD) Overview

JETD seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the Prime Airlines Index. The index measures U.S.-listed companies involved in airlines, aircraft and parts manufacturing, airfreight and logistics, aircraft leasing, and airline and airport operations. As an ETN, JETD provides synthetic exposure without holding underlying securities. It carries an expense ratio of 0.95%. The product is issued by Bank of Montreal under the Max brand and launched in June 2023. Its leveraged inverse structure requires daily rebalancing to maintain the -3x target.

Direxion Daily S&P Biotech Bear 3X ETF (LABD) Overview

LABD seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The equal-weighted index tracks U.S. biotechnology companies classified under the Global Industry Classification Standard (GICS). LABD is an open-ended ETF sponsored by Direxion that uses swaps, futures, and short positions to achieve its objective. It maintains an expense ratio of 1.07% and was launched in May 2015. Daily rebalancing supports the -3x leverage target within the biotechnology sector.

Industry and Thematic Backdrop

The broader environment for both ETFs reflects sector-specific sensitivities to economic cycles, regulatory shifts, and capital market conditions. Airline-related businesses respond to fuel prices, travel demand, and supply-chain dynamics in aerospace. Biotechnology companies face clinical trial outcomes, Food and Drug Administration (FDA) approvals, funding availability, and interest-rate impacts on growth valuations. Macro drivers such as inflation trends, monetary policy expectations, and geopolitical events can influence capital flows into or out of these industries over recent market cycles.

Performance and Positioning Comparison

Over recent weeks and months, performance of both products has tracked the inverse movement of their respective sectors amid shifting economic and policy signals. JETD’s airline focus ties its behavior to travel recovery patterns and commodity price swings, while LABD’s biotechnology exposure links it to healthcare innovation cycles and valuation resets. The -3x daily reset mechanism amplifies volatility for both, creating distinct risk profiles based on sector momentum and earnings trends rather than isolated price fluctuations.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Access the platform to explore current opportunities across leveraged and sector-specific products.

Tickeron AI Verdict

Based on observable structural characteristics, cost efficiency, and diversification within their respective inverse strategies, Tickeron’s AI would currently assign a modestly higher probability of suitability to JETD for investors seeking targeted airline-sector exposure, owing to its slightly lower expense ratio and focused index methodology. LABD remains relevant for biotechnology-specific tactical positioning but carries a marginally higher fee structure.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations